AI Article Synopsis
Article Abstract
In the past 20 years, PCSK9 has been shown to play a pivotal role in LDL cholesterol metabolism and cardiovascular health by inducing the lysosomal degradation of the LDL receptor. PCSK9 was discovered by the cloning of genes up-regulated after apoptosis induced by serum deprivation in primary cerebellar neurons, but despite its initial identification in the brain, the precise role of PCSK9 in the nervous system remains to be clearly established. The present article is a comprehensive review of studies published or in print before July 2023 that have investigated the expression pattern of PCSK9, its effects on lipid metabolism as well as its putative roles specifically in the central and peripheral nervous systems, with a special focus on cerebrovascular and neurodegenerative diseases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10491654 | PMC |
| http://dx.doi.org/10.1016/j.jlr.2023.100426 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pleiotropic Effects of PCSK9 Inhibitors on Cardio-Cerebrovascular Diseases.
Biomedicines
November 2024
Department of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, China.
Cardiovascular disease (CVD) and ischemic stroke (IS) are the primary causes of mortality worldwide. Hypercholesterolemia has been recognized as an independent risk factor for CVD and IS. Numerous clinical trials have unequivocally demonstrated that reducing levels of low-density lipoprotein cholesterol (LDL-C) significantly mitigates the risk of both cardiac and cerebral vascular events, thereby enhancing patient prognosis.
View Article and Find Full Text PDFGene expression patterns of the LDL receptor and its inhibitor Pcsk9 in the adult zebrafish brain suggest a possible role in neurogenesis.
Eur J Neurosci
January 2025
Université de La Réunion, INSERM, UMR 1188, Diabète athérothrombose Thérapies Réunion Océan Indien (DéTROI), Saint-Pierre, La Réunion, France.
Article Synopsis
- The low-density lipoprotein receptor (LDLr) is crucial for lipid metabolism regulation, particularly in mammalian and zebrafish brains.
- Researchers investigated the expression of ldlr genes in zebrafish, finding ldlra expressed later in development and ldlrb present from the early stages.
- The study revealed that these genes, along with pcsk9, are prevalent in adult zebrafish brains, influencing how LDL particles are handled during brain injuries and raising questions about cholesterol balance in brain health.
Inhibition of PCSK9 Protects against Cerebral Ischemia‒Reperfusion Injury via Attenuating Microcirculatory Dysfunction.
Neurochem Res
November 2024
Department of Neurology, Nanjing Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Proprotein convertase substilin/kexin type 9 (PCSK9), a pivotal protein regulating lipid metabolism, has been implicated in promoting microthrombotic formation and inflammatory cascades, thereby contributing to cardiovascular ischemia/reperfusion (I/R) injury. However, its involvement in cerebral I/R injury and its potential role in microcirculation protection remain unexplored. In this investigation, we utilized a middle cerebral artery occlusion/reperfusion (MCAO/R) mouse model to simulate ischemic stroke.
View Article and Find Full Text PDFProprotein convertase subtilisin/kexin type 9 and apelin in fibromyalgia syndrome.
Arch Rheumatol
September 2024
Department of Internal Medicine, Fethi Sekin City Hospital, Elazığ, Türkiye.
Objectives: This study aimed to investigate the potential roles of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and apelin in the etiology of fibromyalgia syndrome (FS).
Patients And Methods: The retrospective study was conducted between May 2022 and February 2023. Fifty-eight female FS patients (mean age: 45.
Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study.
Diseases
October 2024
Cardiology Department, Complejo Hospitalario Universidad de Santiago de Compostela, Santiago de Compostela, 15706 Santiago de Compostela, Spain.
The primary objective of this study was to conduct a cost-utility analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in real-world, comparing their use with standard care for managing cardiovascular disease. A multicenter prospective study was conducted across 12 Spanish hospitals from May 2020 to April 2022, involving 158 patients with hypercholesterolemia or atherosclerotic cardiovascular disease. This study assessed health-related quality of life (QoL) using the EQ-5D-3L questionnaire.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!